Evidence map›Paper›PMID 38162054›Full record

ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2023

[Metabolic Outcomes of Primary Aldosteronism Patients Receiving Adrenalectomy or Spironolactone Treatments].

Chenxiao Xu, Tao Chen, Dan Mo, Tingting Zhang, Fangli Zhou, Haoming Tian, Yan Ren

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chenxiao Xu（ 610041） Adrenal Disease Center, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China.
Tao Chen（ 610041） Adrenal Disease Center, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China.
Dan Mo（ 610041） Adrenal Disease Center, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China.
Tingting Zhang（ 610041） Adrenal Disease Center, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China.
Fangli Zhou（ 610041） Adrenal Disease Center, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China.
Haoming Tian（ 610041） Adrenal Disease Center, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China.
Yan Ren（ 610041） Adrenal Disease Center, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the metabolic outcomes of primary aldosteronism (PA) patients receiving adrenalectomy (ADX) or spironolactone treatment and the contributing factors to the metabolic outcomes. Methods: The clinical data of 70 patients with aldosterone-producing adenoma (APA) and 86 patients with idiopathic hyperaldosteronism (IHA) were retrospectively analyzed. All subjects received confirmatory diagnosis of APA or IHA at the Department of Endocrinology and Metabolism, West China Hospital between March 2018 and October 2020. APA patients underwent ADX, while IHA patients were given spironolactone, a mineralocorticoid receptor antagonist (MRA). After ADX or spironolactone treatment, the outcomes of the metabolic indicators and the inter-group differences between the APA patients and IHA patients were studied. Results: There was no significant difference between the baseline data of the APA group and those of the IHA group in terms of age, sex, duration of hypertension, maximum systolic blood pressure (SBP-max), maximum diastolic blood pressure (DBP-max), body mass index (BMI), fasting blood glucose (FBG), lipid parameters, and renal function. IHA patients had higher waist circumference, serum potassium, and plasma renin activity (PRA) than those of the APA patients (all Conclusion: After treatment, PA patients still may experience abnormal lipid metabolism and deteriorating renal function. Spironolactone therapy may give rise to worse glucolipid metabolism than ADX therapy does.

Indexed as

HyperaldosteronismHypertensionAdrenalectomyAldosteroneHumansPotassiumRetrospective StudiesSpironolactoneAldosteronePotassiumSpironolactoneMetabolic outcomePrimary aldosteronismTherapy

Identifiers

PMID38162054
PMCPMC10752778

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.